Attillaps Holdings is a privately-held biotechnology company focused on developing skin microbiome-based therapies for the treatment of inflammation.  Our novel approach places our clinical candidates in a unique position to target a new microbe thought to be at the root of the etiology of numerous inflammatory diseases.


Attillaps leverages its target discovery and characterization expertise to identify new pathways and develop unique, first-in-class therapies by repositioning compounds to treat dermatology, ophthalmology and autoimmune conditions.